Dr. David H. Harpole Jr.

Dr. David H. Harpole Jr. M.D.

Dr. David Harpole, Jr., MD, is a Vice Chair of Faculty Affairs as well as a member of the Division of Cardiovascular and Thoracic Surgery at the Duke University Health System.

(919) 668-8413
N/A
DUMC 3627 Durham, NC 27710

Dr. David Harpole, Jr., MD, is a Vice Chair of Faculty Affairs as well as a member of the Division of Cardiovascular and Thoracic Surgery at the Duke University Health System. Additionally, Dr. Harpole is an Associate Professor of Surgery and an Assistant Professor of Pathology in the Thoracic Oncology Program at Duke University. Dr. Harpole also holds the prestigious title of Director of the Lung Cancer Prognostic Research Laboratory.

Training, Residency and Fellowship

In 1984, Dr. Harpole graduated from the University Of Virginia School Of Medicine. After getting his degree as a medical doctor, he went to Duke University Medical Center where he completed his residency in 1991. Following his residency, Dr. David Harpole began his fellowship training in thoracic surgery at Duke University from 1991 to 1993. With a thirst for knowledge, he continued with another fellowship, this time completing training in the advanced specialty of thoracic oncology at Dana Farber Cancer Institute at Harvard Medical School. Today he is Board Certified in Surgery and Thoracic Surgery, as well as a member of the American Society of Clinical Oncology and the Society of the Thoracic Surgeons.

Clinical Interests

Dr. David Harpole has a number of clinical interests that include:

Mesothelioma
Thoracic oncology
General thoracic surgery
Benign and malignant disease of the lung, esophagus and mediastinum
Advanced airway and thoracoscopic surgery
Hyperhidrosis palmaris
Research Interests

With new innovations in technology, researchers are getting closer to finding a cure for cancer. Dr. Harpole is among the many physicians who dedicate time toward discovering new methods and treatments to combat cancer. Some of his research interests include:

Non-small cell lung cancer
Evaluation of serum and tissue molecular biologic markers of recurrence in patients with a localize non-small cell lung cancer.
Molecular biologic staging of lymph nodes in patients with non-small cell lung cancer.
The evaluation of the clonality of metastatic tumors in patients with non-small cell lung cancer.
Clinical research activities

Creation of a prospective database for the Duke Thoracic Oncology Program.
A cost and satisfaction evaluation of thoracoscopy and open thoracotomy in patients.
Development of risk associated models of morbidity in patients undergoing general thoracic surgery procedures: The VA Cooperative Surgical Risk Study
A member of the Duke Gastrointestinal Malignancy Research Committee, developing esophageal cancer treatment protocols and outcome studies.
Research and Publications

As a part of his research, Dr. Harpole has been involved in several publications and journal articles regarding various aspects of mesothelioma and thoracic clinical trials. A sample of the papers published by Dr. Harpole et al. includes:

Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, Daley J, Henderson WG, Krasnicka B, Khuri SF. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003 Jan;75(1):217-22; discussion 222. (2003)
Kinch MS, Moore MB, Harpole DH Jr. Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival. Clin Cancer Res. 2003 Feb;9(2):613-8. (2003)
D’Amico TA, Wong TZ, Harpole DH, Brown SD, Coleman RE. Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. Ann Thorac Surg. 2002 Jul;74(1):160-3; discussion 163. (2002)
D’Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg. 2001 Oct;72(4):1144-8. (2001)
Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst. 2001 Dec 19;93(24):1886-8. (2001)
Marom EM, Aloia TA, Moore MB, Hara M, Herndon JE 2nd, Harpole DH Jr, Goodman PC, Patz EF Jr. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001 Aug-Sep;33(2-3):99-107. (2001)
Harpole DH Jr, Gall SA, Rankin JS, Jones RH. Effects of valve replacement on ventricular mechanics in mitral regurgitation and aortic stenosis. Ann Thorac Surg 1996; 62:756-761. (1996)
Harpole DH Jr, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res, 1995; 55:51-56 (1995)
Harpole DH Jr, Marks JR, Richards W, Sugarbaker DJ. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1995; 1:659-664. (1995)

Reference: